MBINBIO@EC2606A(15589.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
MBINBIO@EC2606A
15589.HK
News
View More

"Major Banks" Guosen Securities lists the top ten stocks for foreign capital inflows and outflows in Hong Kong stocks last quarter (Table)

Guotai Junan Securities released a report listing the top ten stocks for foreign capital inflows and outflows in Hong Kong stocks in the fourth quarter of last year. In terms of inflows, INNOVENT BIO ranked first with HKD 6.43 billion, followed by Xiexin Technology and SMIC, with HKD 5.31 billion and HKD 5.28 billion respectively. In terms of outflows, XIAOMI-W topped the list with HKD 50.41 billion, while ALI HEALTH and HSBC HOLDINGS had outflows of HKD 21.13 billion and HKD 16.23 billion respectively

AASTOCKS·
HK
00005
+0.77%
HK
01801
-2.45%
HK
01810
-2.81%
AASTOCKS·
HK
00005
+0.77%
HK
01801
-2.45%
HK
01810
-2.81%

Innovent Biologics: Rising Star in Biopharma

Innovent Biologics is emerging as a leader in China's biopharma sector, shifting from generics to innovative biopharmaceuticals. With revenues projected to reach USD 126.6 billion by 2030, the company has launched 18 products and has a robust pipeline. In Q3 2025, it reported a 40% year-on-year revenue increase, driven by successful oncology drugs. Analysts are optimistic, with a consensus target price indicating a potential 25.5% upside. However, challenges such as regulatory pressures and competition remain. Innovent's focus on innovation positions it for significant growth in the global biopharma landscape.

marketscreener·
HK
01801
-2.45%
marketscreener·
HK
01801
-2.45%

Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial

Innovent Biologics Inc. and Ollin Biosciences reported positive Phase 1b results for IBI324 in a clinical trial for diabetic macular edema and wet age-related macular degeneration. The study showed IBI324's superior outcomes compared to faricimab, with plans to advance to global Phase 3 studies. Full results will be presented at a symposium in February 2026.

Reuters·
HK
01801
-2.45%
Reuters·
HK
01801
-2.45%

Hong Kong stock movement: The innovative drug industry explodes, REMEGEN rises 10.04%

REMEGEN rose 10.04%; Innovent Biologics rose 4.20%, with a transaction volume reaching HKD 1.214 billion; CanSino Biologics rose 5.48%, with a transaction volume reaching HKD 1.058 billion; BeiGene rose 1.92%, with a transaction volume reaching HKD 844 million; Kelun-Biotech rose 4.31%, with a market value reaching HKD 107.3 billion

HK Stock Movers Tracker·
HK
09995
-2.22%
HK
01801
-2.45%
HK
09926
-3.78%
HK Stock Movers Tracker·
HK
09995
-2.22%
HK
01801
-2.45%
HK
09926
-3.78%

Health care roundup: Market talk

Find insight on Innovent, Raffles Medical Group and more in the latest Market Talks covering the Health Care sector.

MSN·
HK
01801
-2.45%
SG
BSL
0.00%
MSN·
HK
01801
-2.45%
SG
BSL
0.00%
Posts
View More
© 2026 Longbridge｜Disclaimer